Viemed (VMD) Completes Buyback: 1.98M Shares for $13.2M

Viemed Healthcare, Inc. announced on September 23, 2025 that it has completed its previously authorized share repurchase program.

Accepted by SEC EDGAR 09/23/2025 - 05:01 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Viemed Healthcare, Inc. announced on September 23, 2025 that it has completed its previously authorized share repurchase program. The company repurchased a total of 1,976,441 common shares for an aggregate purchase price of approximately $13.2 million, before applicable taxes. The announcement was issued via a press release furnished as Exhibit 99.1 to the Current Report and is incorporated by reference. The filing notes the press release and related Item 7.01 information are furnished and not "filed" for purposes of Section 18 of the Exchange Act.

Positive

• Repurchase completed: The company executed the entire authorized program, repurchasing 1,976,441 shares.
• Capital returned to shareholders: Approximately $13.2 million was deployed to repurchase shares, representing completed use of the authorization.

Negative

• No additional detail provided on average repurchase price per share, timing of purchases, remaining authorization history, or financing source.
• Disclosure furnished, not filed, meaning the press release is not submitted as a filed item under Section 18 and carries the limited incorporation treatment described.

Insights

Securities Analyst

TL;DR: The company completed a ~$13.2M buyback of 1.98M shares, closing the authorized repurchase program.

The repurchase completion is a clear, discrete capital deployment event: 1,976,441 shares were bought for approximately $13.2 million, as disclosed. This extinguishes the remaining capacity under the announced program and removes those shares from public float (subject to treasury treatment), which can affect per-share metrics. The filing is procedural and furnished with an exhibit; no additional financial details, authorization limits, timing of purchases, average price per share, financing source, or impact on outstanding share count beyond the totals provided are disclosed in the text.

Corporate Governance Specialist

TL;DR: Completion of repurchase documented; disclosure follows standard furnishing practice without contemporaneous governance commentary.

The 8-K confirms completion and furnishes a press release as Exhibit 99.1. The disclosure follows General Instruction B.2 treatment by furnishing (not filing) Item 7.01 material. There is no disclosure here about board authorization details, any changes in buyback policy, or executive decisions surrounding timing. The report is narrowly focused and does not present new governance actions beyond completing the program.

8-K Event Classification

3 items: 7.01, 8.01, 9.01

3 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Viemed Healthcare (VMD) announce in this 8-K?

The company announced completion of its previously authorized share repurchase program and furnished a related press release as Exhibit 99.1.

How many shares did VMD repurchase under the program?

Viemed repurchased 1,976,441 common shares in total.

What was the aggregate cost of the repurchased shares?

The aggregate purchase price was approximately $13.2 million, before applicable taxes.

When was the repurchase completion disclosed?

The company disclosed completion on September 23, 2025 in the Current Report.

Is the press release considered "filed" with the SEC?

No. The filing states the press release is furnished as Exhibit 99.1 and is not deemed "filed" for purposes of Section 18 of the Exchange Act.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

0001729149false00017291492025-09-232025-09-23

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 23, 2025

Viemed Healthcare, Inc.

(Exact name of registrant as specified in its charter)

British Columbia, Canada

001-38973

N/A

(State or other jurisdiction of incorporation)

(Commission File Number)

(I.R.S. Employer Identification No.)

625 E. Kaliste Saloom Rd. Lafayette, Louisiana						70508
(Address of principal executive offices)						(Zip Code)

(337) 504-3802

(Registrant’s telephone number, including area code) 

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading Symbol(s)			Name of each exchange on which registered
Common shares, no par value			VMD			The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01.     Regulation FD Disclosure

Press Release

On September 23, 2025, Viemed Healthcare, Inc. (the “Company”) issued a press release announcing the completion of its previously authorized share repurchase program, as further described in Item 8.01 below. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

In accordance with General Instruction B.2 of Form 8-K, the information presented in Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information and Exhibit 99.1 be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 8.01     Other Events

On September 23, 2025, the Company announced that it has completed all repurchases authorized under its previously announced share repurchase program. In total, the Company repurchased 1,976,441 common shares for an aggregate purchase price of approximately $13.2 million, before applicable taxes.

Item 9.01.    Financial Statements and Exhibits

(d) Exhibits

Exhibit Number						Description
99.1						Press Release dated September 23, 2025.
104						Cover Page Interactive Data File, formatted in Inline XBRL and included as Exhibit 101

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: September 23, 2025

VIEMED HEALTHCARE, INC.
By:						/s/ Trae Fitzgerald
						Trae Fitzgerald
						Chief Financial Officer